AWM
VIR icon

Abound Wealth Management’s Vir Biotechnology VIR Stock Holding History

Abound Wealth Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16
Closed -$118 – 1330
2024
Q4 		$118 Hold
16
– – ﹤0.01% 1199
2024
Q3 		$120 Hold
16
– – ﹤0.01% 1271
2024
Q2 		$143 Buy
16
+7
+78% +$67 ﹤0.01% 1146
2024
Q1 		$92 Hold
9
– – ﹤0.01% 1273
2023
Q4 		$91 Hold
9
– – ﹤0.01% 1292
2023
Q3 		$85 Hold
9
– – ﹤0.01% 1151
2023
Q2 		$221 Buy
+9
New +$226 ﹤0.01% 1139

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Abound Wealth Management's VIR Position: Q1 2025 in Review

Abound Wealth Management sold out of Vir Biotechnology (VIR) in Q1 2025, closing a stake of 16 shares — an estimated $118 sold.

Abound Wealth Management first reported a position in VIR in Q2 2023 and held it in 7 quarters. The position peaked at $221 in Q2 2023. 233 funds tracked by Wall St. Rank hold VIR as of Q1 2025.

  • Abound Wealth Management reported no remaining Vir Biotechnology position as of Q1 2025 after selling out during the quarter.
  • Abound Wealth Management sold 16 Vir Biotechnology shares in Q1 2025, an estimated $118.
  • Abound Wealth Management first reported a position in Vir Biotechnology in Q2 2023 and held it in 7 quarters.
  • Abound Wealth Management's Vir Biotechnology position peaked at $221 in Q2 2023.
  • 233 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2025.

Based on Abound Wealth Management's 13F filing for Q1 2025, filed 17 Apr 2025.